In patients with primary sclerosing cholangitis, biliary tract cancer is the leading cause of death. Yet very little is known about effective systemic treatments in these individuals. A new study ...

(BPT) – Imagine waking up every day feeling utterly exhausted, no matter how much sleep you get. Now, add an unbearable itch that just won’t go away, dry eyes and mouth, and stomach pain. This is the ...

—A recent study provides genetic evidence linking a higher body mass index (BMI) to an increased risk of primary biliary cholangitis and autoimmune hepatitis but a decreased risk of primary sclerosing ...

A new study published in the journal of Hepatology showed that statin usage was linked to decreased risks of significant ...

Seladelpar is an oral, selective peroxisome proliferator-activated receptor delta agonist. Treatment with seladelpar was associated with an improvement in cholestatis markers in patients with primary ...

A primary biliary cholangitis (PBC) diagnosis can be life-changing. For many, it’s an emotional journey filled with questions, uncertainties and a need to redefine what life looks like with a chronic ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — Healio spoke with James L. Boyer, MD, about phase 3 findings from the RESPONSE trial and the ELATIVE ...

For patients with primary biliary cholangitis, more receiving the peroxisome proliferator-activated receptor delta (PPARδ) agonist seladelpar have a biochemical response and alkaline phosphatase ...

Please provide your email address to receive an email when new articles are posted on . Results presented at The Liver Meeting demonstrated 72% of patients achieved a biochemical response after 182 ...

Seladelpar, an investigational selective agonist of peroxisome proliferator–activated receptor-delta (PPAR-δ), significantly improves liver biomarkers of disease activity and bothersome symptoms of ...

This indication was approved under accelerated approval based on a reduction of alkaline phosphatase. The Food and Drug Administration (FDA) has granted accelerated approval to Iqirvo ® (elafibranor) ...

Primary biliary cholangitis (PBC) is a chronic cholestatic disorder in which symptoms exert a direct influence on patients’ ...